Mecasermin
Also called rhIGF-1, Increlex
Subcutaneous (under the skin)Product label
Research reference
Product label
Increlex pediatric weight-based schedule
0.04–0.08 mg/kg twice daily initially; increases only after at least one tolerated week
Individual growth and safety follow-up; maximum label amount 0.12 mg/kg per dose
Increlex product label ↗When results may show
- When change was measured
- Meal/snack timing and blood-glucose monitoring are essential because severe low blood sugar can occur.
- When to assess
- Individual growth and safety follow-up; maximum label amount 0.12 mg/kg per dose
- Conditions and limitations
- Children aged 2 or older with specified severe primary IGF-I deficiency. Not a healthy-adult muscle-building schedule. Never substitute LR3 or DES variants or copy a per-kilogram amount as a fixed dose.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Sources: Increlex product label
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Mecasermin describe 1–3 mg per administration. Descriptive only, not a recommendation.
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.33× single dose
- Time to steady state
- 30hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Increlex product labelNot a healthy-adult muscle-building schedule. Never substitute LR3 or DES variants or copy a per-kilogram amount as a fixed dose.
Next steps
Mecasermin beginner guideOpen Mecasermin planning worksheetEstimate Mecasermin vial costTrack Mecasermin notes